Cancer Genetics Inc. kicked off the trading day on 10/10/19 with a price increase of 22.14%, equivalent to $0.04 relative change for the day. Taking a more long-term approach, CGIX had a 52-week range of $0.09 to $0.96. At the time of this article’s publishing, this stock is trading at $0.18 after starting the trading session at $0.15. At the time of writing, this stock’s 50-day Moving Average stands at $0.11, while the 200-day Moving Average of this stock is currently $0.20.
Currently, this company’s share volume is sitting at $12592897, but has maintained average daily volume of $4.20M. This stock has generated an average Year to Date volume of $2.64 million, alongside an average 20-day volume of $7.43 million. This publicly-traded company’s shares outstanding now amounts to $57.52 million, simultaneously with a float of $50.09 million. The organization now has a market capitalization sitting at $10.19 million.
Cancer Genetics Inc.(CGIX) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Cancer Genetics Inc.’s current insider ownership accounts for 24.60%, in contrast to 16.20% institutional ownership. According to the most recent latest insider trade that took place on Jan 31 this organization’s Chief Financial Officer bought 150,000 at the rate of 0.23, making the entire transaction hit 34,500 in total value, affecting insider ownership by 150,000. Preceding that transaction, on Jan 31 Company’s Chief Executive Officer bought 185,436 at a price of 0.23, making the whole transaction’s value amount to 42,650. This particular insider is now the holder of 297,636 in total.
If we take a glance at the Ownership summary of Cancer Genetics Inc.’s stock, Institutional holders make up 16.20% of its total stock ownership. All together, they are the legal holders of 57.52M shares. If we focus on the top 3 stockholders for this publicly-traded organization, Perkins Capital Management, Inc. owns 2,983,778 shares, with Renaissance Technologies LLC in 2nd place owning 2,777,125 shares and Geode Capital Management LLC in third place with total ownership of 221,803 shares.
Cancer Genetics Inc. (CGIX) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on 12/30/2018, the organization reported -$0.14 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$0.16) by $0.02.
This company achieved a net margin of -97.84 while generating a return on equity of -224.97. Cancer Genetics Inc.’s full-quarter revenue increased by 40.42%, when compared against the year-ago quarter. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Looking at the long run, market analysts have predicted that Company’s EPS will increase by 40.00% through the next 5 years, which can be compared against the 22.40% growth it accomplished over the previous five years trading on the market.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Cancer Genetics Inc., this organization’s Quick Ratio in the last reported quarter now stands at 0.80. The company has managed to achieve an average true range (ATR) of 0.02. Alongside those, its Beta score is 1.61.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.63 for this organization. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 1.97, whereas its price to cash per share for the last quarter landed at 0.01.